Guggenheim analyst Chalres Zhu lowered the firm’s price target on Ideaya Biosciences to $44 from $48 and keeps a Buy rating on the shares after the company reported Q3 results in line with the firm’s expectations. The firm’s revised price target is adjusted given dilution after recent financing, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IDYA:
- Ideaya Biosciences price target raised to $40 from $35 at Oppenheimer
- Ideaya Biosciences reports Q3 EPS (46c), consensus (49c)
- IDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
- Ideaya Biosciences 5M share Spot Secondary priced at $23.50
- Ideaya Biosciences $125M Spot Secondary; price range $23.50-$24.50
